Giaquinto AN. et al. Breast cancer statistics 2024. CA: A Cancer Journal for Clinicians n/a, https://doi.org/10.3322/caac.21863.

Xu S, Murtagh S, Han Y, Wan F, Toriola AT. Breast Cancer Incidence Among US Women Aged 20 to 49 Years by Race, Stage, and Hormone Receptor Status. JAMA Netw Open. 2024;7:e2353331. https://doi.org/10.1001/jamanetworkopen.2023.53331.

Article  PubMed  PubMed Central  Google Scholar 

Cuzick J, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503. https://doi.org/10.1016/s1470-2045(11)70030-4.

Article  CAS  PubMed  Google Scholar 

Colditz GA, Bohlke K. Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014;64:186–94. https://doi.org/10.3322/caac.21225.

Article  PubMed  Google Scholar 

Stubert J, Dieterich M, Gerber B. Medical prevention of breast cancer. Breast Care (Basel). 2014;9:391–6. https://doi.org/10.1159/000369573.

Article  PubMed  Google Scholar 

Fisher B. et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI: Journal of the National Cancer Institute. 1998;90:1371–1388, https://doi.org/10.1093/jnci/90.18.1371.

Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther. 2009;9:51–60. https://doi.org/10.1586/14737140.9.1.51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goss PE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91. https://doi.org/10.1056/NEJMoa1103507.

Article  CAS  PubMed  Google Scholar 

Colditz GA, Taylor PR. Prevention trials: their place in how we understand the value of prevention strategies. Annu Rev Public Health. 2010;31:105–20. https://doi.org/10.1146/annurev.publhealth.121208.131051.

Article  PubMed  PubMed Central  Google Scholar 

Force UPST. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019;322:857–67. https://doi.org/10.1001/jama.2019.11885.

Article  Google Scholar 

Britt KL, Cuzick J, Phillips K-A. Key steps for effective breast cancer prevention. Nat Rev Cancer. 2020;20:417–36. https://doi.org/10.1038/s41568-020-0266-x.

Article  CAS  PubMed  Google Scholar 

Gronich N, Rennert G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol. 2013;10:625–42. https://doi.org/10.1038/nrclinonc.2013.169.

Article  CAS  PubMed  Google Scholar 

Gandini S, et al. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila). 2014;7:867–85. https://doi.org/10.1158/1940-6207.Capr-13-0424.

Article  CAS  PubMed  Google Scholar 

Mocellin S, Pilati P, Briarava M, & Nitti D. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. J Natl Cancer Inst. 2016;108. https://doi.org/10.1093/jnci/djv318.

Mocellin S, Goodwin A, Pasquali S. Risk-reducing medications for primary breast cancer: a network meta-analysis. Cochrane Database Syst Rev. 2019. https://doi.org/10.1002/14651858.CD012191.pub2.

Article  PubMed  PubMed Central  Google Scholar 

Sterne JA. C, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.). 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Rücker G. Network meta-analysis, electrical networks and graph theory. Research synthesis methods. 2012;3:312–24.

Article  PubMed  Google Scholar 

Salanti G, Ades A, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011;64:163–71.

Article  PubMed  Google Scholar 

R Core Team, R: A Language and Environment for Statistical Computing. 2023. https://www.R-project.org/.

Balduzzi S, et al. netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106:1–40.

Article  Google Scholar 

Vogel VG, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41. https://doi.org/10.1001/jama.295.23.joc60074.

Article  CAS  PubMed  Google Scholar 

Home PD, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009;373:2125–35. https://doi.org/10.1016/s0140-6736(09)60953-3.

Article  CAS  PubMed  Google Scholar 

Gregorio F, et al. Poorly controlled elderly Type 2 diabetic patients: the effects of increasing sulphonylurea dosages or adding metformin. Diabet Med. 1999;16:1016–24. https://doi.org/10.1046/j.1464-5491.1999.00201.x.

Article  CAS  PubMed  Google Scholar 

Lee IM, Cook NR, Manson JE, Buring JE, Hennekens CH. β-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. J Natl Cancer Inst. 1999;91:2102–6.

Article  CAS  PubMed  Google Scholar 

Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-Year results from the MORE trial. Breast Cancer Res Treatment. 2001;65:125–34. https://doi.org/10.1023/A:1006478317173.

Article  CAS  Google Scholar 

Hercberg S. et al. The SU. VI. MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Int Med. 2004;164:2335–2342.

Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings SR. M CA. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Institute. 2004;96:1751-1761, https://doi.org/10.1093/jnci/djh319

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B. Effects of Conjugated Equine Estrogen in Postmenopausal Women with Hysterectomy: The Women’s Health Initiative Randomized Controlled Trial. JAMA. 2004;291:1701–12. https://doi.org/10.1001/jama.291.14.1701.

Article  CAS  PubMed  Google Scholar 

Lee IM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study: a randomized controlled trial. JAMA. 2005;294:56–65.

Article  CAS  PubMed  Google Scholar 

Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Institute. 2005;97:1652–62. https://doi.org/10.1093/jnci/dji372.

Article  CAS  Google Scholar 

Veronesi U, Mariani L, Decensi A, Formelli F, Camerini T, Miceli R, Di Mauro MG, Costa A, Marubini E, Sporn MB, De Palo G. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol. 2006;17:1065–71. https://doi.org/10.1093/annonc/mdl047.

Article  CAS  PubMed  Google Scholar 

Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, Wenger NK. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. The N Engl J Med. 2006;355:125–37.

Article  CAS  PubMed  Google Scholar 

Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85:1586–91.

Article  CAS  PubMed  Google Scholar 

Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, Costa A, Sacchini V, Travaglini R, D’Aiuto G, Oliviero P. Tamoxifen for the prevention of breast cancer: Late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy. J Natl Cancer Institute. 2007;99:727–37. https://doi.org/10.1093/jnci/djk154.

Article  CAS  Google Scholar 

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Institute. 2007;99:283–90. https://doi.org/10.1093/jnci/djk050.

Article  CAS